MXPA02000404A - Formulaciones de hormona de crecimiento. - Google Patents

Formulaciones de hormona de crecimiento.

Info

Publication number
MXPA02000404A
MXPA02000404A MXPA02000404A MXPA02000404A MXPA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A MX PA02000404 A MXPA02000404 A MX PA02000404A
Authority
MX
Mexico
Prior art keywords
growth hormone
temperatures
formulation
formulations
hormone formulations
Prior art date
Application number
MXPA02000404A
Other languages
English (en)
Spanish (es)
Inventor
Bernhard Siebold
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02000404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of MXPA02000404A publication Critical patent/MXPA02000404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MXPA02000404A 1999-07-12 2000-07-11 Formulaciones de hormona de crecimiento. MXPA02000404A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (1)

Publication Number Publication Date
MXPA02000404A true MXPA02000404A (es) 2004-05-21

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02000404A MXPA02000404A (es) 1999-07-12 2000-07-11 Formulaciones de hormona de crecimiento.

Country Status (25)

Country Link
US (1) US20060029635A1 (cg-RX-API-DMAC7.html)
EP (1) EP1194170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2003504346A (cg-RX-API-DMAC7.html)
KR (1) KR20020031388A (cg-RX-API-DMAC7.html)
CN (1) CN1360506A (cg-RX-API-DMAC7.html)
AR (1) AR024728A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386501T1 (cg-RX-API-DMAC7.html)
AU (1) AU775107C (cg-RX-API-DMAC7.html)
BR (1) BR0013162A (cg-RX-API-DMAC7.html)
CA (1) CA2378949C (cg-RX-API-DMAC7.html)
CZ (1) CZ200260A3 (cg-RX-API-DMAC7.html)
DE (1) DE60038118T2 (cg-RX-API-DMAC7.html)
ES (1) ES2300268T3 (cg-RX-API-DMAC7.html)
HK (1) HK1046358A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202189A3 (cg-RX-API-DMAC7.html)
IL (2) IL147253A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000404A (cg-RX-API-DMAC7.html)
NO (1) NO20020151L (cg-RX-API-DMAC7.html)
NZ (1) NZ516507A (cg-RX-API-DMAC7.html)
PL (1) PL353238A1 (cg-RX-API-DMAC7.html)
SI (1) SI1194170T1 (cg-RX-API-DMAC7.html)
SK (1) SK252002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200200034T2 (cg-RX-API-DMAC7.html)
TW (1) TWI247608B (cg-RX-API-DMAC7.html)
WO (1) WO2001003741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US20060165733A1 (en) * 2002-07-09 2006-07-27 Michael Betz Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol
US20060252682A1 (en) * 2003-03-18 2006-11-09 Ares Trading S.A. Liquid growth hormone formulation and process of preparation thereof
US20090029911A1 (en) * 2003-09-25 2009-01-29 Ashley Martin Williams Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
MXPA06011029A (es) * 2004-04-07 2007-01-25 Ares Trading Sa Formulacion liquida de hormona del crecimiento.
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
IN2012DN02861A (cg-RX-API-DMAC7.html) * 2009-11-17 2015-07-24 Ipsen Pharma Sas
BR112014001921B1 (pt) 2011-07-25 2022-05-10 Sandoz Ag Formulação aquosa farmaceuticamente aceitável, método para aumentar a estabilidade de uma formulação aquosa farmaceuticamente aceitável e embalagem principal
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
CN107735429B (zh) 2015-12-10 2021-05-07 三菱瓦斯化学株式会社 光固化性组合物和光学材料
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
EP3811962A4 (en) * 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
KR20230109655A (ko) * 2020-11-16 2023-07-20 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 흐림점이 없는 사전 충전 다회 투여 주입 디바이스, 방법 및 제형
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
IL79552A0 (en) * 1985-07-30 1986-10-31 Int Minerals & Chem Corp Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
DE69110290T2 (de) * 1990-09-21 1995-10-19 Novonordisk As Adaptor.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE69334134T2 (de) * 1992-07-31 2007-12-20 Genentech, Inc., South San Francisco Wässrige Formulierung enthaltend Menschliches Wachstumshormon
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
ES2169351T3 (es) * 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
JP5941496B2 (ja) 2016-06-29
EP1194170B1 (en) 2008-02-20
AR024728A1 (es) 2002-10-23
DE60038118D1 (de) 2008-04-03
CZ200260A3 (cs) 2002-04-17
CA2378949C (en) 2015-03-31
HUP0202189A3 (en) 2003-07-28
CA2378949A1 (en) 2001-01-18
SK252002A3 (en) 2002-06-04
KR20020031388A (ko) 2002-05-01
NO20020151L (no) 2002-03-12
DE60038118T2 (de) 2009-03-05
WO2001003741B1 (en) 2001-04-19
JP2003504346A (ja) 2003-02-04
HK1046358A1 (zh) 2003-01-10
AU5997500A (en) 2001-01-30
TR200200034T2 (tr) 2002-05-21
TWI247608B (en) 2006-01-21
SI1194170T1 (sl) 2008-10-31
ES2300268T3 (es) 2008-06-16
BR0013162A (pt) 2002-05-28
US20060029635A1 (en) 2006-02-09
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15
EP1194170A1 (en) 2002-04-10
JP2014208656A (ja) 2014-11-06
ATE386501T1 (de) 2008-03-15
NO20020151D0 (no) 2002-01-11
WO2001003741A1 (en) 2001-01-18
AU775107B2 (en) 2004-07-15
NZ516507A (en) 2004-02-27
AU775107C (en) 2005-02-24
PL353238A1 (en) 2003-11-03
CN1360506A (zh) 2002-07-24
IL147253A (en) 2007-07-24
HUP0202189A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
MXPA02000404A (es) Formulaciones de hormona de crecimiento.
ES2188607T3 (es) Composiciones enzimaticas liquidas estabilizadas.
AR040526A1 (es) Formulaciuones de hgh en alta concentracion que contienen fenol
Taylor et al. Regulation of pyruvate dehydrogenase in muscle: Inhibition by citrate
US8435730B2 (en) Semen extender composition and methods for manufacturing and using
CN102578079A (zh) 马属动物精液稀释基础液及其配制方法和使用方法
JP2013540104A (ja) 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
PT1389089E (pt) Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
JP2011504881A (ja) モキシフロキサシンおよびデキサメタゾンリン酸エステルを含む局所眼用または局所耳用溶液製剤
CN102014920B (zh) 滴眼剂制剂及其应用
AUPN801296A0 (en) Stabilised growth hormone formulation and method of preparation thereof
EP0284249A1 (en) Lyophilized lymphokine composition
CZ20022654A3 (cs) Farmaceutická kompozice, obsahující Pemetrexed společně s monothioglycerolem, L-cysteinem nebo kyselinou thioglykolovou
CA2463681A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
CN110463688A (zh) 一种羊精液的稀释液以及保存方法
AU566174B2 (en) Process to preserve acid-producing bacteria
EP1231933B1 (en) An aqueous solution formulation of alpha-interferon
Freund et al. Factors affecting the dilution, freezing and storage of human semen
JP3364680B2 (ja) 豚精液保存用希釈液および豚精液の希釈保存法
Shannon et al. Effect of storage temperature on the viability and fertility of bovine sperm diluted and stored in Caprogen
JPS6333327A (ja) 安定化されたフエニレフリン系液剤
CN108077244A (zh) 一种长效猪精液稀释粉
Lee et al. Effects of the ethanol contents on the preparation of low salt Doenzang
CA1289472C (en) Tpa-containing medical composition
KR102123805B1 (ko) 클로렐라의 냉동 보관 방법

Legal Events

Date Code Title Description
FG Grant or registration